28311-23-1

Basic information

• Product Name: 4-(4-Bromophenyl)pyrrolidine-2-one
• Synonyms: 4-(4-Bromophenyl)pyrrolidine-2-one;4-(4-Bromophenyl)-2-pyrrolidinone;4-(4-broMophenyl)pyrrolidin-2-one
• CAS NO: 28311-23-1
• Molecular Formula: C₁₀H₁₀BrNO
• Molecular Weight: 240.11
• Mol File: 28311-23-1.mol

Chemical Properties

• Appearance: /
• Density: 1.485
• CAS DataBase Reference: 4-(4-Bromophenyl)pyrrolidine-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Bromophenyl)pyrrolidine-2-one(28311-23-1)
• EPA Substance Registry System: 4-(4-Bromophenyl)pyrrolidine-2-one(28311-23-1)

Safety Data

• Hazardous Substances Data: 28311-23-1(Hazardous Substances Data)

Upstream product

• 29655-72-9 ethyl 3-(4-bromophenyl)-4-nitrobutanoate 
• 540481-48-9 methyl 3-(4-bromophenyl)-4-nitrobutyrate 
• 422519-72-0 tert-butyl 3-(4-bromophenyl)acrylate 
• 589-87-7 1,4-bromoiodobenzene 

Downstream Products

• 1021917-47-4 6-(4-(5-oxopyrrolidin-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 
• 28311-35-5 C₁₀H₁₂BrNO₂*ClH 
• 1199802-97-5 4-(4-{4-[(4-chlorophenyl)sulfanyl]-1-ethyl-1H-pyrazol-3-yl}phenyl)pyrrolidin-2-one 

Relevant articles and documents

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

Design, synthesis, and biological evaluation of a dansyled amino acid derivative as an imaging agent for apoptosis

To develop a small molecule-based biomarker for in vivo apoptosis imaging, a dansyled amino acid derivative (BNSBA) was designed and synthesized in good yield. The biological evaluation demonstrated that BNSBA selectively binds to apoptotic cancer cells and is localized within the cytoplasm of cells that bound annexin V on the plasma membrane.

HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.